Athira Pharma Stock Investor Sentiment

ATHA Stock  USD 0.41  0.01  2.38%   
About 61% of Athira Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding Athira Pharma suggests that many traders are alarmed. The current market sentiment, together with Athira Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Athira Pharma stock news signals to limit their universe of possible portfolio assets.
  

Athira Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Athira Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
58.2%
53.2%
52.7%
52.8%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at gurufocus.com         
Athira Pharma Inc Reports Annual EPS of -2.52, Narrowing Losses and Reducing Expenses in 2024
Gurufocus Stories at Macroaxis
2 days ago at seekingalpha.com         
Athira Pharma GAAP EPS of -2.52 beats by 0.02
seekingalpha News
3 days ago at www.macroaxis.com         
Acquisition by Worthington Mark of 7767 shares of Athira Pharma at 2.41 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Can Athira Pharma Afford To Invest In Growth?
Yahoo News
over a month ago at news.google.com         
Can Athira Pharma Afford To Invest In Growth - Yahoo Finance
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Athira Pharma, Inc. Short Interest Down 17.6 percent in December
news
over a month ago at simplywall.st         
Insider Buyers Lose Additional US78k As Athira Pharma Dips To US21m
Simply Wall St News at Macroaxis
over a month ago at bizjournals.com         
Bothells Athira Pharma to pay 4M to settle falsified research claims
bizjournals News
over a month ago at news.google.com         
Athira Pharma to Pay 4 Million Over Alleged Research Misconduct - Marketscreener.com
Google News at Macroaxis
over a month ago at news.google.com         
Disposition of 46667 shares by San Martin Javier of Athira Pharma subject to Rule 16b-3
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 8510 shares by Worthington Mark of Athira Pharma at 0.5619 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Disposition of 36667 shares by Worthington Mark of Athira Pharma subject to Rule 16b-3
Yahoo News
over two months ago at finance.yahoo.com         
Athira Pharma Insider Ups Holding By 111 percent During Year
Yahoo News
over two months ago at investing.com         
Athira Pharmas SWOT analysis stock faces challenges after trial setback
Investing News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Andrew Gengos of 5000 shares of Athira Pharma subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Athira Pharma that are available to investors today. That information is available publicly through Athira media outlets and privately through word of mouth or via Athira internal channels. However, regardless of the origin, that massive amount of Athira data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Athira Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Athira Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Athira Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Athira Pharma alpha.

Athira Pharma Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.1512345678Dec2025Feb -35-30-25-20-15-10-50
JavaScript chart by amCharts 3.21.15Athira Pharma Athira Pharma Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Associations 35th Internation...
12/06/2024
2
Athira Pharma Insider Ups Holding By 111 percent During Year
12/18/2024
3
Disposition of 8510 shares by Worthington Mark of Athira Pharma at 0.5619 subject to Rule 16b-3
01/02/2025
4
Disposition of 46667 shares by San Martin Javier of Athira Pharma subject to Rule 16b-3
01/03/2025
5
Insider Buyers Lose Additional US78k As Athira Pharma Dips To US21m
01/17/2025
6
Can Athira Pharma Afford To Invest In Growth
01/28/2025
7
Acquisition by Worthington Mark of 7767 shares of Athira Pharma at 2.41 subject to Rule 16b-3
02/26/2025
8
Athira Pharma Inc Reports Annual EPS of -2.52, Narrowing Losses and Reducing Expenses in 2024
02/27/2025

Complementary Tools for Athira Stock analysis

When running Athira Pharma's price analysis, check to measure Athira Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Athira Pharma is operating at the current time. Most of Athira Pharma's value examination focuses on studying past and present price action to predict the probability of Athira Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Athira Pharma's price. Additionally, you may evaluate how the addition of Athira Pharma to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios